$15.24
-1.76-10.35%
Last update: Nov 5, 4:19 PM
Mineralys Therapeutics Inc
MLYSNASDAQ
The average analyst price target for Mineralys Therapeutics is $45.86, 199.9% above the current price. Of 9 analysts, 7 rate it Buy and 2 Hold. Targets range from $26 to $56. The latest change came on Oct 12, 2026, when UBS initiated coverage of Mineralys Therapeutics with a Neutral rating and a $29 price target.
Price Target Range — 9 Quarters
Analyst Consensus — 9 Analysts
Rating Trend — Last 9 Months
